Abstract:

Aim. Was to analyze atherosclerotic disease dynamics and long-term results (up to 5 years) after implantation of bare-metal stents (BMS) and sirolimus-eluting stents (SES) in patients with multivascular coronary disease

Methods and results. We have analyzed clinicaland angiographic results data of percutaneous coronary interventions (PCI) of 585 patients with multivascular coronary disease during 5-years of follow-up period. 264 patients were treated with BMS, 321 - with SES We used Cypher drug-eluting stents (sirolimus-eluting stents) in the first group and BX Velocity bare-metal stents in the second group of patients

During first year of follow-up the incidence of symptoms reoccurrence in BMS and SES groups was 22,3% and 11,8% (р < 0,05) repeated PCI was performed in 15,6% and 3,9% (р < 0,05), CABG - 2,8% and 0,3% (р < 0,05), the incidence of myocardial infarction (MI) was 1,4% and 0,9%. The restenosis rate in BMS and SES groups was 19,7% and 2,3% (р < 0,05), late thrombosis (LT) - 0,3% and 1,4% The survival without MACE was higher in SES group

During 5 years of follow-up the cumulative incidence of symptoms reoccurrence in BMS and DES groups was 30,7% and 22,7% repeated PCI was performed in 23,9% and 18,1% (р < 0,05), CABG - 6,4% and 4,7%, the incidence of myocardial infarction (MI) was 6,5% and 7,8%. The progression of atherosclerosis in early stented segments in BMS and SES groups was 6,6% and 10,1%, late thrombosis (LT) - 0,4% and 2,1%. There was no difference in survival without MACE between groups

Conclusions. By the end of the first year of follow-up the incidence of angina reoccurrence and repeat revascularization in patients with multivascular coronary disease was higher in BMS group compared with SES group. The survival without MACE was also higher in SES group. By the end of the fifth year of follow-up there was no difference in angina reoccurrence, repeated revascularization and surviva without MACE because the late thrombosis and atherosclerosis progression in early stented segments was more common in DES group. 

References 

1     Henderson R.A. et al. Seven year outcome in the RITA-2 trial. Coronary angioplasty versus medical therapy. Ibid. 2003; 42: 1161-1170.

2.    Pocock S.J. et al. Quality of life after coronary angioplasty or continued medical treatment for anginan. Three year follow up in the RITA-2 trial. J. Am. Col. Cardiol. 2000; 35:907-914.

3.    Sculpher M.J. et al. Coronary angioplasty versus medical therapy for angina. Health service costs based on the Second Randomized Intervention Treatment oj Angina (RITA-2) trial. Eur. Heart. J. 2002; 23: 1237-1239.

4.    Serruys P. W. et al. For the Benestent Study Group. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med. 1994; 331: 489-495.

5.    Hueb W. et а!. The medicine, angioplasty or surgery study (MASS-II). A randomized, controlled clinical trial of three therapeutic strategies for multivessel согоnary artery desease. J. Ат. СоИ. Cardiol.   2004;  43: 1743-1751.

6.    Orlich D. et al. Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J. Am. Coll. Cardiol. 2004; 43: 1154-1160.

7.    Буза В.В., Лопухова В.В., Карпов Ю.А. Поздние тромбозы после имплантации стентов с лекарственным покрытиемКардиология. 2007; 6: 85-86.

8.    Camenzind E., Steg P.G., Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents. А cause for concern. Circulation. 2007; 115: 1440-1455.